AbbVie

Open: 132.93 Close: 133.5 Change: 0.57

The stock market through the eyes of an AI: AbbVie Company Inc Stock.

The game is changing. There is a new strategy to evaluate AbbVie fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AbbVie are: AbbVie, ABBV, stock, Abbvie, Inc, company, year, and the …

Concept Map

Semantic Network

Stock Summary

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenos.

Today's Summary

Dillards, Suzano, Atkore, Nexstar Media Group and AbbVie are part of the Zacks Screen of the Week article. Dillards (DDS), Suzano (SUZ), Atkore (ATKR), Nexstar (NXST) and AbcVie (ABBV) are some of the stocks with high ROE to profit from as market decline.

Today's News

AbbVie Inc. (ABBV) latest stock news | Seeking Alpha. Join now Search for Symbols, analysts, keywords Log in ABBV to view stock analysis. AbbVie to present at Goldman Sachs 44th Annual Global Healthcare Conference on Wednesday, June 14, 2023. The company will announce its second-quarter 2023 financial results on Thursday. Zacks: AbbVie (ABBV) shareholders have earned a 14% CAGR over the last five years. Dillards, Suzano, Atkore, Nexstar Media Group and Abbvie are part of the Zacks Screen of the Week article. Insiders at AbbBVie sold US$8.4m in stock. AbbVie Inc. (NYSE:ABBV) to Issue $1.48 Quarterly Dividend Abbvie Inc.s share price is 134.98 USD today. ABBVie has increased its dividend by an average of 9.2% per year over the last three years. The company has a payout ratio of 53.3%. AbbVie Inc. has a payout ratio of 53.3% meaning its dividend is sufficiently covered by earnings. Equities analysts expect the company to earn $10.99 per share next year, which means the company should continue to be able to cover its $5.92 annual dividend. AbbVie (ABBV) closed the most recent trading day at $137.25, moving -0.27% from the previous trading session. Whales have been targeting a price range from $100.0 to $165.0 for Abbvie over the last 3 months. Dillards, Suzano, Atkore, Nexstar Media Group and AbbVie are part of the Zacks Screen of the Week article. Dillards (DDS), Suzano (SUZ), Atkore (ATKR), Nexstar (NXST) and AbcVie (ABBV) are some of the stocks with high ROE to profit from as markets decline. Antibody-Drug Conjugates: The 21st Century Magic Bullets for Cancer ADC Review. Depatuxizumab Mafodotin did not demonstrate a survival benefit in INTELLANCE-1 Study. AbbVie Inc. is currently overvalued by 9% compared to the current market price of 133.52 USD. Is ABBV stock undervalued or overvalued? Morgan Stanley reiterated coverage of Abbvie (ABBV) with a Overweight recommendation on July 11, 2023. Morgan Stanley Reiterates AbbVies Overweight Recommendation. AbbVie stock slips as Cigna adds Humira biosimilars. Express Scripts, the PBM unit of CignA, pledged to cover three biosimilar targets. Abbvie announced positive topline results from COMMAND, its Phase 3 maintenance study showing positive top-line results.

Stock Profile

"AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; and Genentech, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois."

Keywords

This document will help you to evaluate AbbVie without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AbbVie are: AbbVie, ABBV, stock, Abbvie, Inc, company, year, and the most common words in the summary are: abbvie, stock, abbv, market, price, year, dividend, . One of the sentences in the summary was: Dillards, Suzano, Atkore, Nexstar Media Group and AbbVie are part of the Zacks Screen of the Week article. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #abbvie #stock #abbv #market #price #year #dividend.